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Objectives: Maternal obesity increases the risk of gestational diabetes mellitus (GDM) and 
is positively correlated with neonatal obesity increasing the risk of adiposity in both young 
and adult offspring. Maternal secreted factors from adipose tissue such as adipokines and 
inflammatory cytokines may regulate fetal growth. This study investigated associations 
between maternal adipokines and inflammatory markers at late gestation, and neonatal 
anthropometric characteristics in mothers with and without GDM. 
Material and methods: The study included 65 women with GDM and 65 pregnant women 
with normal glucose tolerance evaluated at the time of term elective Caesarean section. 
Adiponectin, leptin, resistin, adipsin, neutrophil gelatinase-associated lipocalin (NGAL), 
nerve growth factor (NGF), monocyte chemotactic protein-1 (MCP-1) and tumor necrosis 
factor-alpha (TNF-alpha) concentrations were measured in maternal serum by the multiplex 
immunoassay using Magpix technology. C-reactive protein (CRP) was measured with a 
particle-enhanced turbidimetric immunoassay and neonatal anthropometric variables were 
assessed. The association of birthweight with individual biomarkers was analyzed using 
multivariate logistic regression adjusted for maternal factors. 
Results: Adiponectin, leptin, resistin, adipsin, NGAL and NGF were not significantly 
associated with higher birthweight. The maternal factors in association with higher 
birthweight observed in GDM were CRP, MCP-1 and TNF-alpha levels. Regression 
analysis showed that TNF-alpha was an independent risk factor for higher birthweight (p = 
0.046). 
Conclusions: These results suggest an involvement of maternal inflammatory markers at 
late gestation and fetal growth in mothers with GDM, and that TNF-alpha could play a 
major role.  






Obesity is a major clinical problem in women of reproductive age worldwide [1]. It 
is currently estimated that three in four women of reproductive age in Mexico are classified 
as overweight or obese [2]. Maternal obesity increases the risk of infertility, stillbirth, 
gestational diabetes mellitus (GDM), preeclampsia, pregnancy-induced hypertension, 
thromboembolism and complications during delivery. In addition, maternal obesity is 
positively correlated with neonatal and childhood obesity in the offspring with negative 
consequences that include increased risk of metabolic syndrome and type 2 diabetes 
mellitus (T2DM) later in life [3]. 
The prevalence of GDM, which is a state of glucose intolerance that develops 
during pregnancy, is rising worldwide [4]. In Mexico, it ranges from 10.3% to 30.1%, 
depending on the diagnostic criteria used [5, 6]. GDM increases the risk of T2DM, and 
associate with higher risk of large for gestational age (LGA) products, who subsequently 
develop an increased risk of obesity and diabetes in adulthood [7]. It is established that the 
transport of nutrients other than glucose from the mother to the fetus as amino acids and/or 
lipids could contribute to excessive fetal growth [8].  
As pregnancy increases adiposity, attention has been drawn to the role of maternal 
factors associated with adipose tissue (adipokines and inflammatory markers) in mediating 
fetal growth [9–12]. Adiponectin, the most commonly found adipokine, is produced 
exclusively by adipose tissue and is suggested to have various properties, including insulin-
sensitizing, anti-atherogenic, and anti-inflammatory. Deficient concentrations in plasma of 
adiponectin correlate with GDM and obesity [13]. This may be due to reduced levels of 
adiponectin causing a reduction of glucose uptake in skeletal muscle, accompanied by an 
increase in production of hepatic glucose. In addition, studies have shown that maternal 
adiponectin is inversely associated with birthweight [14, 15]. 
Leptin is released into the circulation in white adipose tissue in proportion to the 
amount of lipid stores and it has been suggested that increased maternal leptin 
concentrations in the third trimester of pregnancy may be attributed to the placenta, and not 
maternal adipose tissue. Leptin regulates placental growth, nutrient transfer, angiogenesis, 
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and trophoblast invasion and enhances the mobilization of maternal fat stores to the fetus. 
Moreover, most studies have found increased leptin concentrations in GDM [13] and 
maternal leptin levels have been shown to be associated to fetal growth, and an association 
between maternal leptin levels during pregnancy and offspring adiposity at two years of age 
has also been observed [16]. 
Tumor necrosis factor-alpha (TNF-alpha) is a multifunctional cytokine, and a 
central regulator of inflammation. TNF-alpha is defined as a cytokine which is the product 
of monocytes, macrophages, T-cells, neutrophils, fibroblasts and adipocytes. TNF-alpha 
induces insulin resistance in skeletal muscle and adipose tissue. Plasma TNF-alpha levels 
correlate with body mass index (BMI) and insulin resistance. High TNF-alpha levels from 
early gestation are associated with subsequent GDM [13]. There is also evidence that TNF-
alpha transcript is significantly increased in placentas from women with GDM at term, 
compared to non-diabetic control women [17]. It appears that TNF-alpha can activate 
docosahexaenoic acid, an essential ω-3 polyunsaturated fatty acid that accumulates in 
placenta of offspring from mothers with GDM, causing increased adiposity in newborns 
[18].  
C-reactive protein (CRP) is a nonspecific marker of inflammation in the body that 
increases gradually throughout pregnancy to approaching labor. Monocyte chemotactic 
protein-1 (MCP-1) is a chemokine secreted by monocytes, macrophages, lymphocytes, 
endothelial cells, decidua, myometrium and placenta. It is a chemotactic factor that attracts 
and activates monocytes and macrophages into sites of inflammation. MCP-1 increases 
during normal pregnancy and even more during labor, suggesting that MCP-1 modulates 
the immune system as pregnancy advances. Several studies have reported that maternal 
serum CRP and MCP-1 concentrations are negatively correlated to birthweight [19, 20]. 
Adipsin is a protease with close homology to human complement D. It is secreted 
from muscle, lung, peripheral nerves, placenta and adipose tissue. Adipsin is the rate-
limiting enzyme in the formation of acylation stimulating protein, a factor contributing to 
lipid storage in adipose tissue. Adipsin levels are significantly higher in obesity and 
positively related to BMI. Furthermore, higher levels of adipsin have been reported in 
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GDM [21]. A recent study found no association between cord blood adipsin and 
birthweight [22]. 
Neutrophil gelatinase-associated lipocalin (NGAL), also known as lipocalin 2, is a 
glycoprotein secreted by neutrophils, epithelial cells and adipocytes. It is abundantly 
present in damaged epithelia during inflammation and cardiovascular disease. NGAL 
concentrations are elevated in obesity, T2DM and GDM [23].  
Resistin is a pro-inflammatory adipokine expressed in adipocytes, pancreatic islets, 
mononuclear cells, macrophages, placenta and liver. In rodents, resistin represents a clear 
pathogenic factor in the severity of insulin resistance. However, in humans, this adipokine 
correlates with insulin resistance as a consequence of obesity. Some studies have suggested 
that elevated circulating resistin is a risk factor for GDM. One study found mRNA 
expression of gene-encoded resistin was increased in adipose tissue from GDM when 
compared to a non-GDM group, and the expression level was related to insulin resistance 
[24].  Conflicting findings have been found regarding cord serum resistin and birthweight 
[25, 26].  
Nerve growth factor (NGF) is one of the neurotrophic factors, and associates with 
the survival, development and function of central nervous system basal forebrain 
cholinergic neurons, as well as peripheral embryonic and sympathetic sensory neurons. In 
addition, NGF appears to play an important role in placental and fetal growth. In small for 
gestational age (SGA) infants born at term, NGF levels are markedly higher than 
appropriate for gestational age (AGA) and LGA infants [27]. The NGF gene is also found 
in white adipose tissues, and it increases in the presence of inflammatory cytokines, 
including TNF-alpha. In addition, levels of circulating NGF are upregulated in obesity and 
metabolic syndrome [28]. 
In summary, most studies related to maternal adipokines and birthweight have 
yielded inconsistent findings. In addition, very few studies have investigated maternal CRP, 
MCP-1, resistin, adipsin, NGAL and nerve growth factor NGF levels. The aim of this study 
was to determine whether there is an association between maternal plasma adiponectin, 
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leptin, resistin, adipsin, NGAL, NGF, CRP, MCP-1 and TNF-alpha concentrations at late 
gestation, GDM, and the fetal growth.  
MATERIAL AND METHODS 
Research Design and Study Population 
Data for this cross-sectional study was obtained from a larger study of women who 
were recruited from the Hospital of Gynecology and Obstetrics 3, Medical Center La Raza, 
IMSS (Mexico City), or the Hospital of Gynecology and Obstetrics 221, IMSS (Toluca, 
State of Mexico), for an elective caesarean section, for a study on adipokine gene 
expression in omental adipose tissue in GDM (data not published).  The original study was 
approved by the Institutional Review Board of the Instituto Mexicano del Seguro Social 
(IMSS) in Mexico City (R-2018-785-026) and all participants gave written informed 
consent. The study included singleton births to mothers over 18 years of age from January 
2019 to December 2019. To eliminate any confounding effects from the labor process, only 
those undergoing a term (37–41 weeks of gestation) elective Caesarean section were 
considered for the study (indications for Caesarean included breech presentation, previous 
Caesarean section, and/or when macrosomia was suspected by ultrasonography at 38 weeks 
of gestation). Women with pre-gestational diabetes or hypertension and autoimmune, 
immunosuppressive, kidney, heart, infectious diseases or smoking and alcohol habits as 
well as pregnancies complicated by fetal anomalies were excluded from the study. The 
present study included term births to both normal glucose tolerant (NGT) women and 
women with GDM. Gestational age was estimated by last menstrual period and confirmed 
by ultrasonographic measurements at first trimester in all subjects. All pregnant women 
were screened for GDM at 24–28 weeks of gestation and were classified according to the 
results of the screening. Women with GDM were diagnosed according to the International 
Association of Diabetes and Pregnancy Study Groups criteria by one or more abnormal 
glucose value during a 75 g-oral glucose tolerance test (OGTT), with fasting levels > 5.1 
mmol/L, 1h >10 mmol/L or 2 h > 8.5 mmol/L. Management after GDM diagnosis was 
started with medical nutrition therapy (1600–1800 kcal/day with restriction of 
carbohydrates to 35–40%), and moderate physical activity (30 minutes of moderate-
intensity aerobic exercise at least five days a week) and subsequent evaluation of glycemic 
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control with fasting glucose and postprandial blood glucose at two hours after meals at 2–4 
week intervals. Insulin therapy (0.7–1.0 units/kg of body weight daily) was prescribed for 
women who did not achieve glycemic control with diet (fasting glucose levels < 5.27 
mmol/L, and postprandial blood glucose values < 6.66 mmol/L at 2 hours). Of the women 
with GDM, 75% (n = 49) were treated by diet and moderate physical activity only, and the 
remainder (n = 16) received the aforementioned insulin therapy for glycemic control. 
Information about current and previous pregnancies was collected on a baseline 
questionnaire using medical records. Demographic characteristics included maternal age, 
history of GDM and family history of diabetes in a first-degree relative. Maternal pre-
pregnancy BMI was calculated from patient-reported pre-pregnancy weight and the height 
measured during the first visit of gestation. BMI at the time of delivery was also calculated.  
Birth size measures 
Anthropometric measures (weight, length, foot length, head circumference, chest 
circumference, abdominal circumference, and ponderal index) were assessed at birth in the 
term infants. Ponderal index was calculated as 100 x [birthweight (g)/length (cm3)]. The 
infants were classified as small for gestational age (SGA), appropriate for gestational age 
(AGA) or large for gestational age (LGA) according to weight for gestational age of 
Mexican children [29]. LGA and SGA were defined as > 90th and < 10th percentile, 
respectively. Macrosomia was considered in cases of birth weight ≥ 4000 g. Information 
about the infant’s sex, and Apgar scores came from birth certificates. Apgar scores were 
noted soon after delivery at one minute and at five minutes. 
Biochemical analysis 
Maternal fasting blood samples for biochemical analysis were obtained by 
venipuncture together with the samples for routinely performed laboratory tests at the day 
of the scheduled Caesarean section. The samples could clot for at least 30 minutes before 
centrifugation at 1000 g, which was continued for 15 minutes. Serum aliquots were frozen 
at −70° C until assayed. Levels of glucose, total cholesterol, high-density lipoprotein 
(HDL) cholesterol and triglycerides were measured in fresh samples on an ARCHITECT 
Plus c4000 Clinical Chemistry Analyzer (Abbot Diagnostics, Abbott Park, IL, USA). 
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Levels of low- density lipoprotein (LDL) cholesterol were estimated with use of the 
Friedewald formula. CRP was measured with a particle-enhanced turbidimetric 
immunoassay (MULTIGENT CRP Vario kit; Sentinel CH, Milan, Italy) on the 
ARCHITECT Plus c4000 Clinical Chemistry Analyzer (Abbot Diagnostics, Abbott Park, 
IL, USA). Adiponectin, leptin, resistin, adipsin, NGAL, NGF, MCP-1, TNF-alpha, and 
insulin were measured through the multiplex immunoassay using Magpix technology 
(Milliplex Map, Billerica, MA, USA). Insulin resistance was calculated using the 
homeostasis model assessment for insulin resistance (HOMA-IR) method, where HOMA-
IR = fasting insulin concentration [μU/mL] x fasting glucose concentration [mmol/L]/22.5 
[30]. 
Statistical analysis 
Kolmogorov-Smirnov test was used to assess data distribution. Results are 
presented as medians with interquartile range (IQR). Differences between groups were 
analyzed by Mann-Whitney test and Kruskal-Wallis test. To assess the correlation of the 
data, Spearman’s correlation test was performed. Logistic regression analysis with LGA as 
a dependent variable was performed with adjustment for the following covariates: length of 
gestation, infant sex, maternal demographic factors, maternal anthropometric measures, 
plasma glucose levels, lipids, insulin, adipokines and inflammatory proteins. We used IBM 
SPSS Statistics 23.0 (IBM SPSS Inc., Chicago, IL) for statistical analysis, and p < 0.05 was 
defined as significant. 
RESULTS 
The demographic and clinical data of mothers are shown in Table 1. Women with 
GDM had a higher age, weight, BMI, and parity, previous GDM, family history of diabetes 
and higher glucose levels at OGTT screening and glucose concentration at late gestation 
than women with normal glucose tolerance. They did not significantly differ from women 
without GDM in maternal weight gain at the time of term elective Caesarean section, total 
cholesterol, triglycerides, HDL, LDL, insulin and HOMA-IR. 
Results of the adipocitokines are presented in Table 2. There were no significant 
differences in adiponectin, leptin, resistin, NGAL, NGF, and CRP levels between subjects 
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with GDM and controls. Women with GDM had higher adipsin, MCP-1, and TNF-alpha 
levels. These observed differences did not remain after adjusting for age and weight, and 
insulin treatment did not significantly affect adipokine levels between women taking 
insulin therapy and those not. 
Elevated pre-pregnancy maternal BMI in GDM and NGT subjects, was found to be 
positively associated with adipsin (r = 0.320, p = 0.002), leptin (r = 0.369, p = 0.001), 
MCP-1 (r = 0.410, p = 0.001), and TNF-alpha levels (r = 0.341, p = 0.001). 
Gestational age at delivery was significantly lower among GDM in comparison with 
healthy pregnant women (Tab. 3). However, offspring of mothers with GDM had higher 
weight, height, and ponderal index than offspring of mothers without GDM. The rate of 
LGA was significantly higher in the GDM group than in patients with a non-GDM 
pregnancy. The occurrence of macrosomia was markedly higher in GDM group; there were 
ten macrosomic newborns in GDM and one in the NGT group. The rate of girls, foot 
length, head circumference, chest circumference, abdominal circumference, and Apgar 
score did not significantly differ between both groups. 
Pre-pregnancy BMI, biochemical maternal parameters and adiponectin, leptin, 
resistin, adipsin, NGAL and NGF were not significantly associated with higher birthweight. 
The maternal factors in association with higher birthweight observed were CRP, MCP-1, 
and TNF-alpha levels. Among women with GDM, the median maternal plasma 
concentrations of CRP and MCP-1 showed no significant differences between mothers of 
AGA and LGA neonates (Fig. 1). However, the median maternal plasma CRP and MCP-1 
concentration were higher in mothers of LGA neonates with GDM than in mothers with 
NGT and AGA newborns. Furthermore, among women with GDM, the median maternal 
plasma TNF-alpha concentration was higher in women with an LGA neonate than in those 
with an AGA newborn, and TNF-alpha concentration was higher in women with GDM and 
LGA neonate than in those with NGT and AGA newborn. On logistic regression analysis, 
the significant predictor of having a LGA infant, after adjustment for covariates, was TNF-




In our study, we evaluated the association between specific maternal adipokines and 
inflammatory markers at late gestation and fetal growth in mothers with GDM. Notably, 
offspring of mothers with GDM had higher weight, height and ponderal index than 
offspring of mothers without GDM, and the rate of LGA was significantly higher in the 
GDM group than in patients with a non-GDM pregnancy. Gestational diabetes mellitus is a 
common predisposing factor for having infants who are born large for gestational age and 
subsequently develop an increased risk of obesity and T2DM in adulthood [7]. Maternal 
blood glucose level is associated with birthweight. However, even with strict glycemic 
control, women with GDM have higher frequency of macrosomic infants [31]. It has been 
suggested that other nutrients, such as triglycerides and amino acids, contribute to excessive 
fetal growth [8]. In this study, we did not find any relation of either maternal fasting 
glucose or triglyceride concentration at term with newborn weight. Similarly, none of the 
metabolic measures, such as glucose values at OGTT, total cholesterol, HDL, LDL, insulin 
and HOMA-IR, were associated with birth weight. Moreover, although mean values of 
OGTT indices at screening were significantly elevated in GDM over healthy controls, 
indicating increased insulin resistance in GDM group, there was no difference between 
studied groups regarding lipid profile, insulin and HOMA-IR at term. This could be a 
consequence of metabolic control performed in GDM, which was evaluated at 2–4-week 
intervals until delivery. Notably, maternal weight gain during pregnancy did not differ 
between the study groups. 
Recently, maternal adipokines and inflammatory cytokines have been identified as 
independent risk determinants of fetal overgrowth [9–12]. In the present study, fetal growth 
was associated with higher CRP, MCP-1, and TNF-alpha levels in mothers with GDM. The 
association between newborn weight and TNF-alpha was independent of established risk 
factors of GDM such as age, prepregnancy BMI, parity, and family history of T2DM. 
Similarly, recent findings from Kumarathasan et al., demonstrated a proinflammatory status 
in LGA healthy mothers, as higher inflammatory index compared to the AGA group [19].  
Some studies have reported, contrary to our finding, that maternal serum CRP and 
MCP-1 concentrations are negatively correlated to birthweight. Thus, CRP at 28 weeks’ 
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gestation in healthy pregnant women, as well as maternal MCP-1 at third trimester (32–34 
weeks), were associated with SGA births [19, 20]. The discrepancy between our finding 
and others might be related to gestational age at sampling. Further, our population differs 
from others in relation to GDM, which could affect the maternal inflammatory state. GDM 
associates with changes in inflammatory profiles, both maternal, fetal and placental, 
mirrored by an increase in circulating inflammatory molecules [32]. 
Obesity is associated with pathologic sequelae, including chronic inflammation and 
adipocyte dysregulation. Maternal obesity, defined by an elevated pre-pregnancy BMI, is a 
risk factor for fetal macrosomia. In our study, maternal BMI was not associated with 
birthweight. However, maternal BMI was in correlation with the serum adipsin, leptin, 
MCP-1, and TNF-alpha levels, suggesting that one of the main sources of cytokine 
production is the adipose tissue, although it has also been documented that the feto-
placental unit could also be an important source of TNF-alpha and leptin [13, 17]. 
In the current study, we did not find an association between maternal adipokines 
adiponectin, leptin, adipsin NGAL, NGF and resistin levels and fetal growth. Previous data 
have shown that some of these adipokines are associated with fetal growth. However, most 
studies have examined maternal adipokines in midpregnancy, or are focused on cord blood. 
In our study, maternal adipokines were measured at the time of Caesarean section. It has 
been demonstrated that blood levels of adipokines change throughout pregnancy in relation 
to the increased fat accretion in the first two trimesters of pregnancy and to the changes in 
clearance in latter stages of pregnancy. In addition, the gestational diabetes participants in 
our study had higher pre-pregnancy BMI, parity, and birthweight than pregnant controls, 
which are factors associated with higher circulating blood volume. The increase in plasma 
volume would result in lower circulating adipokine levels. Other discrepancies may also be 
due to the different genetic backgrounds or environmental condition of the populations 
studied, study design, sample size of the population, the diagnosis criteria of GDM patients, 
the status of glycemic control, and the assay methods used to measure adipokines.  
The cross-sectional design together with the limited sample size, must be considered 
as a limitation of our study. We did not assess the associations between the adipokines at 
various points of time in gestation and birth outcomes. We also relied on self-reported pre-
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pregnancy weight, which is susceptible to reporting bias. Besides, the difference in age and 
BMI between women with GDM and women with a non-GDM pregnancy must be 
considered, although adjustments for these variables were made. In addition, there was a 
lack of HbA1C, and cord plasma measurements and of other, more specific, measures of 
maternal adiposity, that is, intra-abdominal maternal visceral adipose tissue (VAT). BMI 
conveys no information about the quantity, quality, location, or metabolic function of fat 
depots. Measurement of VAT by ultrasound in early pregnancy strongly predicts GDM and 
is associated with birthweight [33, 34]. Excess VAT leads to increased release of fatty acids 
and secretion of pro-inflammatory substances, with consequent changes in fetal growth.  
Strengths of this study include the assessment of several maternal adipokines, while 
much of the prior literature is focused on cord blood or neonatal blood and the control of 
numerous pregnancy factors, including mode of delivery, gestational age, maternal fasting 
status at delivery and maternal smoking. 
Overall, the major present findings reveal that circulating maternal CRP, MCP-1, 
and TNF-alpha are higher in term GDM and LGA neonates than in those with term NGT 
and AGA newborns. Although it is not possible to determine exactly if the source of these 
inflammatory markers is placenta or adipose tissue, this provides a further evidence for a 
possible association of these inflammatory markers with metabolic processes in the feto-
placental unit involved in fetal growth. This inflammatory profile can alter developmental 
programming and have long-lasting influence on offspring. In support of this, Perrin et al. 
[35], in a cohort of infants born prior to 28-weeks’ gestation, reported that obesity at age 
two years is predicted by perinatal systemic inflammation.  
CONCLUSIONS 
These results suggest an involvement of maternal inflammatory markers at late 
gestation and fetal growth in mothers with GDM, and that TNF-alpha could play a major 
role. Further mechanistic studies are necessary to investigate the precise roles of these 
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Table 1. Characteristics of women with and without GDM 
 NGT (n = 65) GDM (n = 65) p 
Maternal age (years) 26 (22–31) 32 (28–35) 0.001 
Pregravid weight (kg) 60.0 (54.8–67.0) 78.1 (63.5–96.5) 0.001 
Weight at delivery (kg) 70.3 (65.7–77.3) 85.2 (72.5–104.5) 0.001 
Pre-pregnancy BMI (kg/m2) 25.1 (23.0–27.1) 32.5 (26.3–38.3) 0.001 
BMI at delivery (kg/m2) 29.6 (27.0–31.5) 34.8 (30.8–41.4) 0.001 
Maternal weight gain (kg) 10.2 (7.1–12.5) 8.3 (4.2–12.3) 0.202 
Parity n (%) 
 Nulliparous 









Family history of diabetes n 
(%) 
7 (10.8) 23 (35.4) 0.004 
Past history of GDM n (%) 0 (0.0) 12 (18.5) 0.001 
Blood glucose at OGTT 
(mmol/L) 
   
  Fasting 4.0 (3.8–4.2) 5.4 (4.6–5.8) 0.001 
  1 h 7.5 (6.5–8.8) 12.8 (11.0–13.0) 0.001 
  2 h 6.4 (5.5–7.4) 9.8 (8.7–10.5) 0.005 
Fasting glucose at delivery 
(mmol/L) 
4.2 (3.8–4.8) 4.7 (4.1–5.3) 0.05 
Triglycerides at delivery 
(mmol/L) 
2.9 (2.5–3.6) 3.4 (2.2–3.9) 0.280 
HDL at delivery (mmol/L) 2.5 (2.2–3.0) 2.4 (1.9–3.0) 0.319 
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LDL at delivery (mmol/L) 1.8 (1.3–2.5) 1.4 (0.84-2.1) 0.081 
Total cholesterol at delivery 
(mmol/L) 
60.1 (52.0–67.0) 55.8 (49.3–66.0) 0.188 
Fasting insulin at delivery 
(pmol/L) 
56.0 (37.6–82.7) 60.4 (43.4–81.7) 0.902 
HOMA-IR at delivery 1.4 (0.9–2.3) 1.7 (1.3–2.5) 0.149 
Data are presented as medians (interquartile range) as well as counts and percentages 
NGT — normal glucose tolerant; GDM — gestational diabetes mellitus; BMI — body 
mass index; OGTT — oral glucose tolerance test; HDL — high-density lipoprotein 




Table 2. Maternal adipokines and inflammatory markers for normal pregnancy and GDM 
at delivery 
 NGT (n = 65) GDM (n = 65) p 
Adiponectin 
(pg/mL) 
213.5 (77.6–766.4) 220.9 (64.6–605.1) 0.490 
Resistin (pg/mL) 54.6 (38.6–68.8) 43.9 (32.4–62.9) 0.097 
Adipsin (pg/mL) 2.5 (1.9–3.1) 3.1 (2.4–3.9) 0.011 
NGAL (pg/mL) 164.9 (112.0–234.7) 159.7 (109.7–247.2) 0.520 
NGF (pg/mL) 2.1 (1.6–2.6) 2.1 (1.6–2.9) 0.487 
Leptin (pg/mL) 7.4 (4.7–11.3) 8.4 (4.9–17.0) 0.538 
CRP (nmol/L) 6.9 (3.7–10.8) 9.5 (5.0–22.9) 0.096 
MCP-1 (pg/mL) 93.3 (68–137) 126.5 (102.4–165.2) 0.005 
TNF-alpha (pg/mL) 2.9 (2.3–3.5) 3.9 (2.8–4.7) 0.006 
Data are presented as medians (interquartile range)  
NGT — normal glucose tolerant; GDM — gestational diabetes mellitus; NGAL — 
neutrophil gelatinase-associated lipocalin; NGF — nerve growth factor; CRP —  C-reactive 




Table 3. Neonatal characteristics grouped by maternal glucose tolerance status during 
pregnancy 
 NGT (n = 65) GDM (n = 65) p 
Gestational age (weeks) 39 (38–40) 38 (38-39) 0.013 
Sex, female 30 (46.2) 41 (63.0) 0.109 







Birth length (cm) 49 (48–50) 50 (49–52) 0.037 
Ponderal index (g/cm3) 2.5 (2.4–2.76) 2.7 (2.5–2.95) 0.05 
Nenonatal foot length (cm) 8 (7–8) 8 (7–8) 0.560 
Neonatal head circumference 
(cm) 
34 (33.25–35) 35 (34–36) 0.084 
Neonatal chest circumference 
(cm) 
33 (32–34) 32 (31–34) 0.510 
Neonatal abdominal 
circumference (cm) 
30 (30–32) 31 (29–33) 0.412 
Birth weight for gestational age n 
(%) 
  Appropriate for gestational age 









Macrosomia n (%) 1 (0.65) 10 (6.5) 0.001 
Apgar 1´ Score 8 (8–8) 8 (8–8) 0.639 
Apgar 2´ Score 9 (9–9) 9 (9–9) 0.519 
Data are presented as medians (interquartile range) as well as counts and percentages; 







Figure 1. Box and whisker plots of serum CRP, MCP-1 and TNF-alpha levels between the 
study groups and/or cases of an LGA product. Among women with GDM, there were no 
statistically significant differences in concentrations of CRP and MCP-1 in maternal plasma 
between patients with AGA and LGA products. However, the median maternal plasma 
CRP and MCP-1 concentration were higher in pregnant women with GDM and LGA 
neonates than in those with NGT and AGA newborns. Furthermore, among women with 
GDM, the maternal plasma concentrations of TNF-alpha were higher in cases of GDM and 
LGA neonate than in NGT and AGA newborn. NGT — normal glucose tolerant; GDM —
gestational diabetes mellitus; AGA — appropriate for gestational age; LGA — large for 
gestational age; CRP — C-reactive protein; MCP-1— monocyte chemotactic protein-1; 
TNF-alpha — tumor necrosis factor-alpha 
